PLX
Protalix·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Revenue Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PLX
Protalix Biotherapeutics, Inc.
A biopharmaceutical company that uses plant cell technology to produce recombinant proteins
2 University Plaza
, Suite 100
, Hackensack
, NJ 07601
Focus on the development and commercialization of recombinant therapeutic proteins with the company's proprietary ProCellEx protein expression system.
Protalix Biotherapeutics, Inc., was originally incorporated in Florida in April 1992 and re-incorporated in Delaware in March 2016. The Company is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by the proprietary ProCellEx plant cell protein expression system. The company is the first and only FDA-approved company to express suspension proteins through plant cells. The company's unique expression system represents a new way to develop recombinant proteins on an industrial scale. The company's strategic focus is to develop custom complex recombinant therapeutic proteins produced primarily through ProCellEx, while genetically engineering and chemically modifying proteins before and after production. The company intends to carry out such engineering and modification to provide additional clinical benefits by improving the biological properties of therapeutic proteins (e.g., glycosylation, half-life, immunogenicity).
Earnings Call
Q3/2025
Estimate EPS0.05
Actual EPS0.03
Estimate Revenue17.87M
Actual Revenue17.67M
Protalix BioTherapeutics' Q3 2025: Contradictions Emerge on PRX-115 Trial Timelines, Chiesi Expansion, Elfabrio Dosing, and Cash Runway
Nov 13,2025 10:28
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS--
Actual EPS-0.05
Estimate Revenue21.60M
Actual Revenue10.11M
Protalix BioTherapeutics Q1 2025: Unpacking Contradictions in Revenue, Market Opportunities, and Clinical Trials
May 20,2025 01:15
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS--
Actual EPS0
Estimate Revenue13.49M
Actual Revenue15.66M
Protalix's Q2 2025: Unpacking Contradictions in Fabry Disease Market Strategy and Clinical Development
Aug 14,2025 12:54
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PLX has released its 2025 Q3 earnings. EPS was reported at 0.03, versus the expected 0.05, missing expectations. The chart below visualizes how PLX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PLX has released its 2025 Q3 earnings report, with revenue of 17.85M, reflecting a YoY change of -0.60%, and net profit of 2.35M, showing a YoY change of -27.22%. The Sankey diagram below clearly presents PLX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
